A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia

Trial Profile

A Multicenter, Randomized, Double-blind, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of HGP0412 and HIP1402 in Patients With Benign Prostatic Hyperplasia

Completed
Phase of Trial: Phase III

Latest Information Update: 18 Oct 2016

At a glance

  • Drugs Tamsulosin (Primary)
  • Indications Benign prostatic hyperplasia
  • Focus Therapeutic Use
  • Sponsors Hanmi Pharmaceutical
  • Most Recent Events

    • 10 May 2016 Primary endpoint has been met. (Total International Prostate Symptom Score), as per an abstract presented at the 111th Annual Meeting of the American Urological Association.
    • 10 May 2016 Results presented at the 111th Annual Meeting of the American Urological Association
    • 01 May 2016 Status changed from recruiting to completed, as per an abstract presented at the 111th Annual Meeting of the American Urological Association.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top